Gonzalez, Brian D. http://orcid.org/0000-0001-5108-5735
Eisel, Sarah L.
Qin, Bo
Llanos, Adana A. M.
Savard, Josée
Hoogland, Aasha I.
Jim, Heather
Lin, Yong
Demissie, Kitaw
Hong, Chi-Chen
Bandera, Elisa V.
Funding for this research was provided by:
National Cancer Institute (K01 CA211789, K01 CA193527, K99 MD013300, R01 CA185623, P01 CA151135, R25 CA090314, P30 CA016056, HHSN261201300021I)
National Heart, Lung, and Blood Institute (R25 HL105444)
National Cancer Institute (R01 CA185623S1, P30 CA072720-5929)
Breast Cancer Research Foundation
Centers for Disease Control and Prevention (NU5U58DP003931-05-00)
Article History
Received: 7 May 2020
Accepted: 16 September 2020
First Online: 29 September 2020
Compliance with ethical standards
:
: HJ: Red Hill Biopharma, Janssen Scientific Affairs. BG: SureMed Compliance, Elly Health. All the other authors declare that they have no conflict of interest.
: The study protocol (ID no. Pro2017000069) was approved by the Institutional Review Board at Rutgers, The State University of New Jersey, and Roswell Park Comprehensive Cancer Center.
: All participants provided written informed consent before participating.
: All authors have consented to publishing this manuscript.
: The codes that support the findings of this study are available on request from the corresponding author.